... Longitudinal magnetic resonance imagingbased assessment of vascular changes and radiation response in androgen- sensitive prostate carcinoma xenografts under androgenexposed and androgen- deprived conditions ... contrast-enhanced magnetic resonance imaging; DWMRI: diffusion-weighted magnetic resonance imaging; PCa: prostate cancer; PSA: prostate specific antigen; RMSE: root mean square error; RT: radiotherapy; ... carried out the animal experiments, MRI data acquisition and analysis, participated in ANN simulations and wrote the manuscript MK developed software and performed the ANN simulations, and contributed...
... cytoplasmic antibodies, anti-double-stranded DNA antibodies, anti-mitochondrial M2 antibodies (anti-Mi2), anti-signal recognition particle (anti-SRP) antibodies, anti-Jo-1 antibodies and anti-polymyositis/scleroderma ... autoimmune polymyositis, and anti-PM-Scl antibodies are found in 25% of patients with concomitant polymyositis and scleroderma [8-10] Although cancer- associated myopathy can be of inflammatory origin ... polymyositis, although anti-Jo-1 antibodies are found in 18% to 55% of these patients, anti-Mi-2 antibodies are found in 4% to 9%, anti-SRP antibodies are found in 4.8% to 11% of patients with autoimmune...
... 82: 342 Shulman MJ, Karam JA and Benaim EA Prostate- specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen- independent prostatecancer Urology ... Brown J and Tangen C Bone mineral density in patients with prostatecancer without bony metastases treated with intermittentandrogensuppression Urology 2004; 64: 1182 Petrylak DP, Tangen CM, ... ascorbic acid and cancer 25 years later Integr Cancer Ther 2005; 4:32 Lamson DW and Plaza SM The anticancer effects of vitamin K Altern Med Rev 2003; 8: 303 De Loecker W, Janssens J, Bonte J and Taper...
... AR-positive advanced prostatecancer Figure Androgen and alternative therapyfor advanced prostatecancer After androgen ablation therapy, androgen treatment will retard the growth and progression ... castration-resistant prostatecancer [39,46-48] IntermittentAndrogen Deprivation therapy is a strategy to periodically perform and terminate the androgen ablation therapy, therefore patients in “off -androgen ... for metastatic prostatecancer [6] More than 80% of men with advanced prostate cancers respond to androgen ablation therapy, resulting in tumor shrinkage and reduction of serum PSA [6] Anti-androgens...
... have been radically treated forprostatecancer by one radiation oncologist with RA Data gathered for these prostatecancerpatients included the indication for radiation therapy This was either ... modulated radiotherapy - a comparison among prostatecancerpatients treated in an Australian centre Radiation Oncology 2011 6:108 Submit your next manuscript to BioMed Central and take full advantage ... our audit, 30 prostatecancerpatients treated radically with RA by one radiation oncologist were found to be treated with acceptable toxicity In re-planning eight prostatecancerpatients treated...
... months for all patients The prostate was delineated on a CT-scan and a margin of mm was applied to the prostate and seminal vesicles to create a planning target volume (PTV) Patients received an ... Criteria (CTC) and late toxicity according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) scale Item Number of patients (%) Grade ... biochemical and local failure in patients with distended rectum on the planning CT forprostatecancer radiotherapy Int J Radiat Oncol Biol Phys 2005, 62:965-973 Dehnad H, Nederveen AJ, van der Heide...
... Twenty-six patients received combined androgen blockade (CAB) consisting of antiandrogen and gonadotropin releasing hormone analogue (GnRH) Three patients received antiandrogen monotherapy Pre-irradiation ... in 24 (61%) patients Hormonal therapy A total of 29 patients (74%) received hormonal therapy (HT), either neoadjuvant, concomitant or adjuvant, with a median duration of months (range, – 24 months) ... Statistical analysis Descriptives include absolute and relative frequencies for categorical variables, median and range for quantitative variables The primary endpoint was the occurrence of acute and...
... of the first 16 QQ patients (lane 1-16) with the In -For and Deletion-Rev primer pair (upper panel) and In -For and In-Rev primer setup (lower panel); lane 17 = mouse tail DNA, lane 18 = water control ... in up to 13% of all US prostatecancer cases [6] and three other variants contribute to familial prostatecancer risk in the Japanese population [7], whereas no significant association with disease ... basis foran ELISA to detect XMRV-specific antibod- ies in the sera of prostatecancerpatients One fragment spanning the region from amino acids to 245 of Env and two overlapping fragments spanning...
... tested both in ovarian cancer cell lines and in a subcutaneous nude mice model for ovarian cancer The results showed high killing potential in ovarian cancer cell lines and a significant tumor growth ... therapeutic vector for ovarian cancer The level of H19 transcript in human ovarian cancer cell lines We determined the level of H19 RNA in different human ovarian cancer cell lines Total RNA was ... Israel for providing OCAF from patients 16 17 18 19 20 21 22 23 References 10 11 12 13 14 15 NCI: National Cancer Institute [http://www .cancer. gov /cancer topics/types/ovarian] Cannistra SA: Cancer...
... studies of our group and others, the transcriptional regulatory sequences of the H19 and IGF2 genes emerged as candidates forcancer targeted therapy H19 and IGF2 (the human P3 and P4 promoters) ... patient CancerTherapy 2005, 3:249-266 Cooper MJ: Noninfectious gene transfer and expression systems forcancer gene therapy Semin Oncol 1996, 23:172-187 Kouraklis G: Gene therapyfor cancer: from ... models for bladder cancer Expression of IGF2-P4 and H19 transcripts in heterotopic subcutaneous tumors In order to develop a model for heterotopic bladder tumors, T24P or HT-1376 human bladder cancer...
... found in various human cancers including non-smallcell lung cancer, ovarian cancer, breast cancer, colon cancer, pancreatic cancer, liver cancer, oral cancer, head and neck cancer and neuroblastoma[12-20] ... Soltermann A, Kristiansen G: Periostin is up-regulated in high grade and high stage prostatecancer BMC Cancer 2010, 10:273-281 Wall NR, Shi Y: Small RNA: can RNA interference be exploited for therapy? ... Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancerCancer Res 2006, 66:6928-6935 17 Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher...
... found in various human cancers including non-smallcell lung cancer, ovarian cancer, breast cancer, colon cancer, pancreatic cancer, liver cancer, oral cancer, head and neck cancer and neuroblastoma[12-20] ... Soltermann A, Kristiansen G: Periostin is up-regulated in high grade and high stage prostatecancer BMC Cancer 2010, 10:273-281 Wall NR, Shi Y: Small RNA: can RNA interference be exploited for therapy? ... Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancerCancer Res 2006, 66:6928-6935 17 Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher...
... metastases is not relevant for metastatic disease that is predominantly sclerotic at baseline, as can occur in a number of cancers and is particularly common in prostatecancer As an alternative to ... planar and/or single-photon emission computed tomography (SPECT) imaging in prostate and other cancers [13-18] PET also offers the inherent advantage of superior quantitative accuracy over planar ... substudy of an open-label phase trial of Alpharadin in patients with bone metastases and castration-resistant prostatecancer Repeated 18F-fluoride PET imaging, PSA and ALP assessments were performed...
... tumor Background Prostatecancer is the most frequently diagnosed cancer and the second leading cause of cancer- related deaths for males in the USA One promising approach in prostatecancer diagnosis ... some malignant cell lines [1, 2] The presence of GRPR has been documented in small cell lung cancers [3], prostate cancers [4, 5], breast cancers [6-8] and others [9] In prostate cancer, the ... 64Cu/NOTA-[D-Tyr6,βAla11,Thi13,Nle14]BBN(6-14) β monomer and dimers forprostatecancer PET imaging Patrick Fournier1, Véronique Dumulon-Perreault1, Samia Ait-Mohand1, Réjean Langlois1, François Bénard2, Roger Lecomte1,...
... except for dose and lung cancer type (Table 1) Sixteen (30%) and 37 (70%) patients presented with and without extracranial disease, respectively KPS ranged from 50 to 100 (median, 90) All patients ... responsible for the primary concept and the design of the study; DCW, NC, ZM and SB performed the data capture and analysis NC and DCW drafted the manuscript; DCW and CC performed the statistical analysis; ... delivery Conclusions This analysis of the outcome of 53 lung cancerpatients with BM treated with WBRT and RTB reveals an increase in OS and PFS forpatients treated with higher Casanova et al Radiation...
... Factor analysis of the Expanded ProstateCancer Index Composite (EPIC) in a patient group after primary (external beam radiotherapy and permanent iodine-125 brachytherapy) and postoperative radiotherapy ... dose, prostate volume, PTV, AUC for bladder and rectum, organ volumes within any of the isodoses 10-100%, percentage of patients with neoadjuvant hormonal therapy) did not differ significantly for ... Kerndl S, Keller M, Busch R, Molls M, Zimmermann FB: Longitudinal analysis of quality of life in patients receiving conformal radiation therapyforprostatecancer Strahlenther Onkol 2010, 186:46-52...
... [1] The median number of pancreatic cancerpatients enrolled per study was 49.5 (range 8-4913 patients) In studies that provided baseline demographic information on pancreatic cancer patients, ... including lung cancer and head and neck cancers [39-41] The sensitivity and specificity of FDG-PET/ CT in the diagnosis and evaluation of pancreatic cancer were reportedly 71-100% and 64-95%, respectively, ... stations was calculated and analyzed by Japan Pancreas Society (JPS) Classification [14] For all 5954 patients with pancreatic cancer (including head and body/tail of pancreas), commonly involved...
... its use prior to radiotherapy for rectal cancer [9] Many reported cases involved the use of large tissue expanders forpatients requiring post-operative adjuvant radiotherapy for large retroperitoneal ... literature review and organised planning CT and radiotherapy; DK inserted and removed the tissue expander and supervised writing of manuscript All authors read and approved the final manuscript Competing ... Paris, France 22 retroperitoneal sarcoma and pelvic cancer adjuvant pelvis & abdomen open ? ? 30-65 Gy heaviness (n = 1) flank pain (n = 1) Burnett et al 2000 Los Angeles, [11] USA cervical cancer...
... radiotherapy as boost for organ-confined prostatecancer Technol Cancer Res Treat 2010, 9:575-582 Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M: Stereotactic body radiotherapy for organ-confined ... decision-making, in general, and more so in prostatecancer [1] Thus late rectal and urinary damage became a major concern in prostate cancer; and many studies have been dedicated to the search for correlations ... (WP) radiotherapy-irradiation of prostate, seminal vesicles, and lymph nodes followed by a prostate boost (116 patients, 59%); and prostate- only (PO) radiotherapy-irradiation of prostate and seminal...
... the prostate apex Nevertheless, CT scan is still widely used forprostatecancer planning, being the standard imaging technique for most radiotherapy Institutes where access to MRI for planning ... conformal radiotherapy forprostatecancer J Urol 2002, 167:539-542 Mulhall JP, Yonover P: Correlation of radiation dose and impotence risk after three-dimensional conformal radiotherapy forprostate ... conformal radiotherapy forprostatecancer Urology 2001, 57:955-959 Roach M, Winter K, Michalski JM, et al: Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate...